Literature DB >> 2585025

Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease.

R Bataille1, D Chappard, C Marcelli, P Dessauw, J Sany, P Baldet, C Alexandre.   

Abstract

In order to clarify the mechanisms involved in the occurrence of lytic bone lesions (BL) in multiple myeloma (MM), we have compared the presenting myeloma-induced histological bone changes of 14 previously untreated MM patients with lytic BL with those of seven MM patients lacking lytic BL at presentation despite similar myeloma cell mass. A major unbalanced bone remodeling (increased bone resorption with normal to low bone formation) was the characteristic feature of patients presenting lytic BL. Furthermore, this unbalanced process was associated with a significant reduction of bone mass. Unexpectedly, a balanced bone remodeling (increase of both bone resorption and bone formation, without bone mass reduction) rather than a true lack of an excessive bone resorption was the usual feature of patients lacking lytic BL. Our current work clearly shows that a majority (72%) of patients with MM present an important unbalanced bone remodeling at diagnosis, leading to bone mass reduction and bone destruction (unbalanced MM). Some patients (20%) retain a balanced bone remodeling with initial absence of bone destruction (balanced MM). Few (8%) patients have pure osteoblastic MM without bone destruction.

Entities:  

Mesh:

Year:  1989        PMID: 2585025     DOI: 10.1200/JCO.1989.7.12.1909

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  43 in total

1.  Introduction to the special issue on the microenvironment of bone metastasis.

Authors:  Rebecca Silbermann
Journal:  Cancer Microenviron       Date:  2011-12

Review 2.  Proteasome inhibitors and bone disease.

Authors:  Ya-Wei Qiang; Christoph J Heuck; John D Shaughnessy; Bart Barlogie; Joshua Epstein
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

3.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

Review 4.  Identify multiple myeloma stem cells: Utopia?

Authors:  Ilaria Saltarella; Aurelia Lamanuzzi; Antonia Reale; Angelo Vacca; Roberto Ria
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

5.  Bone anabolic agents for the treatment of multiple myeloma.

Authors:  Sonia Vallet; Noopur Raje
Journal:  Cancer Microenviron       Date:  2011-12-03

Review 6.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

Review 7.  Extravasation and homing mechanisms in multiple myeloma.

Authors:  Isabelle Vande Broek; Karin Vanderkerken; Benjamin Van Camp; Ivan Van Riet
Journal:  Clin Exp Metastasis       Date:  2007-10-19       Impact factor: 5.150

8.  Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma.

Authors:  M Laroche; M Attal; C Dromer
Journal:  Clin Rheumatol       Date:  1996-07       Impact factor: 2.980

Review 9.  Synstatin: a selective inhibitor of the syndecan-1-coupled IGF1R-αvβ3 integrin complex in tumorigenesis and angiogenesis.

Authors:  Alan C Rapraeger
Journal:  FEBS J       Date:  2013-02-24       Impact factor: 5.542

10.  Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma.

Authors:  Wenjie He; Amitabha Mazumder; Tuere Wilder; Bruce N Cronstein
Journal:  FASEB J       Date:  2013-05-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.